Weight Loss Medicine

Our product range includes a wide range of orligal 120 mg orlistat 120 mg capsule, mounjaro 2.5mg solution for injection tirzepatide 2.5 mg and mounjaro 5mg solution for injection tirzepatide 5 mg.

Orligal 120 Mg Orlistat 120 Mg Capsule

Request Callback

₹ 500 Get Latest Price

Strength120 mg
Pack TypeStrip
Brand NameOrligal
ManufacturerSignature
UsagesFor weight loss and weight management
CompositionOristat
Country of OriginMade in India
Orligal 120mg Tablet is a medicine used in the treatment of obesity. It helps the body in blocking the absorption of fats from the small intestines and stomach. This way it can help reduce calorie intake and weight loss over time.

Mounjaro 2.5mg Solution for Injection Tirzepatide 2.5 mg

Request Callback

₹ 5500 Get Latest Price

Strength2.5 mg
Packaging Size0.5 ml
Packaging TypeInjection
BrandMounjaro 2.5
ManufacturerEli Lilly and Company India Pvt Ltd
CompositionTirzepatide (2.5mg)
Mounjaro 2.5mg Solution for Injection is a prescription medicine used to improve blood sugar control in adults with type 2 diabetes and support weight management in individuals who are overweight and those with obesity. It works by mimicking natural hormones to enhance insulin secretion and regulate appetite.

Mounjaro 5mg Solution for Injection Tirzepatide 5 mg

Request Callback

₹ 6800 Get Latest Price

Strength5 mg
Packaging Size0.5 ml
Packaging TypeInjection
BrandMounjaro
ManufacturerEli Lilly and Company India Pvt Ltd
CompositionTirzepatide (5mg)
Mounjaro 5mg Solution for Injection is a prescription medicine used to improve blood sugar control in adults with type 2 diabetes and support weight management in individuals who are overweight and those with obesity. It works by mimicking natural hormones to enhance insulin secretion and regulate appetite.
X

Contact Us

Girish (Global Sales Head)
Cure International
Ground Floor, Plot No 38, Sushila Society, Sai Mandir Road, State Bank Of India Atm, Sugat Nagar
Nagpur - 440026, Maharashtra, India

Get Directions
Send Email
Share: